Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study

• DOI: 10.1016/j.amsu.2022.103303
• Publication Date: 2022-01-29T23:40:42Z
• Authors: Gusti Noor Ramada...; Resti Yudhawati; Munawaroh Fitriah
• Keywords: Procalcitonin; Cross-sectional study

Coronavirus disease 2019 (COVID-19) is a new health problem discovered in thus requires biomarkers that can detect early tissue damage. Soluble receptor for advanced glycation end-products (sRAGE) biomarker be used to identify lung damage.Analyzing the association of serum sRAGE on COVID-19 severity.This study employed cross-sectional design with consecutive sampling method. It was conducted from May 2020-October 2021. The number participants this 145 which were divided into 2 groups (non-severe = 47 and severe 98). Association severity analyzed using chi-square test, Fisher's exact independence t-test, Mann Withney Spearman's rank test p-value <0.05.The results blood analysis showed several components such as leukocytes (9896.51 ± 4949.64/μL; z 2.431; p 0.015), lymphocytes (13.55 8.48%; 2.256; 0.024), neutrophils (78.91 10.50%; 2.464; 0.014), procalcitonin (0.92 3.22 ng/mL; 3.323; 0.001), CRP (8.59 7.62 mg/L; 2.114; 0.034), D-dimer (4360.29 7797.81 2.186; 0.029), fibrinogen (474.58 168.90 mg/dL; t 0.383; 0.703). There significant comparison values non-severe group (0.78 [0.63-1.00] ng/mL) (1.47 [0.97-2.25] r 7.154; <0.001). between (r 0.598; cut-off value 0.985 ng/mL. This obtained sensitivity 73.5%, specificity 74.5% OR 8.077 AUC 0.868 95% CI.There there also difference two groups.